Abstract. The severe acute respiratory syndrome-associated coronavirus-2 (SARS-CoV-2) poses a threat to human life worldwide. Since early March, 2020, coronavirus disease 2019 (COVID-19), characterized by an acute and often severe form of pneumonia, has been declared a pandemic. This has led to a boom in biomedical research studies at all stages of the pipeline, from the in vitro to the clinical phase. In line with this global effort, known drugs, currently used for the treatment of other pathologies, including antivirals, immunomodulating compounds and antibodies, are currently used off-label for the treatment of COVID-19, in association with the supportive standard care. Yet, no effective treatments have been identified. A new hope stems from medical oncology and relies on the use of immune-checkpoint inhibitors (ICIs). In particular, amongst the ICIs, antibodies able to block the programmed death-1 (PD-1)/PD ligand-1 (PD-L1) pathway have revealed a hidden potential. In fact, patients with severe and critical COVID-19, even prior to the appearance of acute respiratory distress syndrome, exhibit lymphocytopenia and suffer from T-cell exhaustion, which may lead to viral sepsis and an increased mortality rate. It has been observed that cancer patients, who usually are immunocompromised, may restore their anti-tumoral immune response when treated with ICIs. Moreover, viral-infected mice and humans, exhibit a T-cell exhaustion, which is also observed following SARS-CoV-2 infection. Importantly, when treated with anti-PD-1 and anti-PD-L1 antibodies, they restore their T-cell competence and efficiently counteract the viral infection. Based on these observations, four clinical trials are currently open, to examine the efficacy of anti-PD-1 antibody administration to both cancer and non-cancer individuals affected by COVID-19. The results may prove the hypothesis that restoring exhausted T-cells may be a winning strategy to beat SARS-CoV-2 infection.

Contents

1. Introduction
2. SARS-CoV-2 immunopathology
3. Management of COVID-19: Prevention, diagnosis and treatment
4. Role of computational biology in the response to COVID-19
5. Immune-checkpoint inhibitors against COVID-19: A lesson learnt from cancer
6. Conclusions and future perspectives

1. Introduction

In December, 2019, following an outbreak in a fish market in Wuhan (Hubei, China), an infection leading to severe pneumonia rapidly and uncontrollably spread worldwide. The World Health Organization (WHO) declared the status of a
pandemic threat on March 11, 2020 (1), leading all countries to impose lockdowns with devastating socio-economic consequences.

The infection is caused by a highly pathogenic coronavirus, the severe acute respiratory syndrome associated coronavirus-2 (SARS-CoV-2), which is the identified etiological agent of the outbreak, named coronavirus disease 2019 (COVID-19) (2).

Despite global lockdown measures adopted by most countries, as of October 11, 2020 over 37 million COVID-19 cases and 1 million deaths have been reported globally, with half of these cases and deaths reported in the regions of the Americas (3).

SARS-CoV-2 transmission occurs through respiratory droplets, via direct person-to-person contact, with an incubation period of approximately 2 to 12 days following exposure (4). The symptoms of COVID-19 caused by viral infection of the lower respiratory tract include dry cough, fever, fatigue, hypoxia and hypogeusia. The infection may rapidly degenerate to pneumonia, and it can be associated with mild complications, including dyspnea, lymphocytopenia, myalgia, or with more severe comorbidities, including significant hypoxia, associated with the appearance of the acute respiratory distress syndrome (ARDS) (5). Due to ARDS, a non-negligible proportion of COVID-19-affected patients may require oxygen therapy and admission to an intensive care unit (ICU), as the ARDS may be swiftly followed by septic shock and multi-organ dysfunction, thus resulting in a 1 to 4% case fatality rate (6).

Viral genome sequencing generated from samples of 5 patients hospitalized with pneumonia led to the identification of this novel SARS-CoV-2 as part of the β-coronaviridae genera, exhibiting an 88% identity to the sequence of 2 bat-derived CoVs. In fact, bats are considered reservoir hosts for CoVs and, it is considered that SARS-CoV-2 originated from bats, later crossing species before infecting humans (7). Additionally, SARS-CoV-2 exhibits an 80 and 50% identity, respectively, with the genome of 2 other clinically relevant human-β-CoV, the SARS-CoV and Middle East respiratory syndrome coronavirus (MERS-CoV) (8). SARS-CoV-2 emerged in 2002 in China, and caused an outbreak in 26 countries, with a case fatality rate of 9.5%. MERS-CoV originated in 2012 in Saudi Arabia, spreading to 27 countries, with a case fatality rate of 34.4% (8). Therefore, SARS-CoV-2 is considered the third highly pathogenic human-adapted CoV of the 21st century, representing a threat for human health with a heavy global impact (9).

To preserve humanity from this noxious CoV, biomedical research is proceeding at a rapid pace, with the intention of developing a vaccine and/or a therapy to prevent and/or eradicate the virus (10).

The present review article reports up-to-date knowledge of SARS-CoV-2 and COVID-19, with particular attention being paid to novel research approaches aimed at identifying old and novel compounds for the treatment of COVID-19, as well as all therapeutic options currently tested. Among these, the importance of modulating the host immune system is widely discussed, with particular emphasis on the clinical testing of a drug currently used in oncology, the immune-checkpoint inhibitor (ICI) anti-programmed death-1 (PD-1) blocking antibody.

2. SARS-CoV-2 immunopathology

SARS-CoV-2 is a single-stranded positive-sense RNA virus, whose RNA-genome is approximately 30 Kb in length, with a 5’-CAP and a 3’-poly-A tail and containing 10 open reading frames (ORFs) (11,12). Genomic variations of SARS-CoV-2 have been observed; however, further studies are warranted in order to determine whether differently virulent strains may be associated with the differential infection severity range observed in patients with COVID-19 (13).

To enter the host cells, SARS-CoV-2, similar to SARS-CoV, binds to the extracellular enzymatic domain of the single pass transmembrane angiotensin-converting enzyme 2 (ACE2) receptor (14). Physiologically, ACE2 negatively modulates blood pressure by degrading the vasoconstrictor angiotensin II peptide (15). SARS-CoV-2 binding is mediated by the viral glycoprotein spike (S), which also determines the crown-shaped aspect of the virus (16). The difference between SARS-CoV-2 and SARS-CoV is that SARS-CoV-2 possesses a furin cleavage site within the S protein secondary sequence. This is likely to increase virus pathogenicity as cleavage of the S domain during protein synthesis highly increases the affinity for the ACE2 receptor (17), subsequently promoting SARS-CoV-2 endocytosis inside the target cell (18).

ACE2 receptor is expressed by alveolar epithelial cells, but also by lung endothelial cells, and, distally, by heart, lung, kidney, intestinal and neuronal cells. Whether SARS-CoV-2 is able to infect organs located far from the lungs (by directly binding ACE2 receptor in other cells distant from the primary site) is currently under evaluation (19). Within the alveoli, resident dendritic cells (DCs) and macrophages may also be invaded by the SARS-CoV-2, although it remains unclear as to whether this occurs via primary viral infection or through the phagocytosis of epithelial and endothelial pre-infected apoptotic cells (20).

After entering host cells, SARS-CoV-2 uses the host cellular replication machinery to synthesize the RNA negative strand and to produce up to 10 protein products, including the 4 structural proteins S, envelope (E), nucleocapsid (N) and membrane (M) proteins. The viral particles take shape inside the endoplasmic reticulum-Golgi intermediate cellular compartment. Once formed, the host vesicles containing the virus fuse with the plasma membrane, thereby releasing multiple copies of the replicated SARS-CoV-2 into the intercellular space, ready to spread to other cells (21).

As SARS-CoV-2 is a cytopathic virus, infected cells become deeply injured and may undergo cell death upon infection. For this reason, viral infection can trigger extensive lung damage (22). In particular, within infected alveolar cells, a peculiar type of inflammatory cell death termed pyroptosis is observed. Pyroptosis is associated with a concurrent endothelial leakage and triggers an acute pro-inflammatory host immune response, mediated by the intracellular activation of the NLRP3 inflammasome (23-25).

Following SARS-CoV-2 infection, a high rate of immune inflammatory cell infiltration within the alveolar space enhances the local synthesis and secretion of cytokines [interferon (IFN)-α, IFN-β, IFN-γ, tumor necrosis factor (TNF)-α, TGFβ], granulocyte-macrophage colony-stimulating factor (GM-CSF), interleukin (IL)-1β, IL-6, IL-8, IL-12, IL-18,
forms of COVID-19. In particular, a recent preliminary report of T-cells may be a leading cause of the severe and critical NKG2A (44).

Additionally, natural killer (NK) cells decrease in number as well as exhaustion (such as mucin-3, PD-1, NKG2A) (42,43).

Activation at early stages to exhaustion. As a consequence, COVID-19 infection, the T-cell status shifts from extreme blood count of both CD4\(^+\) and CD8\(^+\) cells. In patients with COVID-19 who have succumbed to the disease, the lung presents diffused bilateral alveolar damage and the formation of a hyaline membrane with the thickening of the alveolar wall (51). Moreover, in a number of cases, a strong accumulation of mononuclear cells and infiltrating macrophages is also present, which occludes the air-exposed surfaces. Following electron microscopy analyses, the SARS-CoV-2 virus has been detected inside bronchial and alveolar type 2 cells. Apart from the lungs, kidney hemorrhage, inflamed liver and neuron degeneration have often been recorded in a number of patients (51). Additionally, in 70% of deaths, a disseminated intravascular coagulation has also been observed (52). Although vascular endothelial cells express ACE2 receptor, the exact mechanism of such a coagulopathy has not yet been clarified. Moreover, apart from being isolated from the lungs, SARS-CoV-2 viral particles have also been found in urine and stool samples (53). A total of 70% of deaths of patients with COVID-19 were caused by ARDS, whereas the other 30% by complications, including sepsis and multi-organ failure (possibly related to the CS) (54). Sepsis and septic shock have been reported in severe and critical cases (55). In almost 80% of patients with COVID-19 with sepsis, SARS-CoV-2 is the only etiological agent found in both blood and lower respiratory tract specimens, indicating that it is a viral sepsis. Viremia and sepsis are hypothesized to play a pivotal role in the dissemination of SARS-CoV-2 and the subsequent multi-organ damage (56,57).

The immune system of the host plays a fundamental role in the individual outcome of SARS-CoV-2. Based on available data from patients with COVID-19, a recently published medical hypothesis postulated that in mild COVID-19 cases, lung resident macrophages initiated the anti-viral inflammatory response. In turn, macrophages may contain the infection assessed the increased expression of NKG2A and PD-1 inhibitory receptors on T- and NK cell surfaces of patients with COVID-19, suggesting that anticaner immunotherapy could be repurposed as a first line of defense to trigger SARS-CoV-2 clearance (45). In general, SARS-CoV-2 infection may negatively affect the host antiviral immunity at an early stage of the infection process. Importantly, both dysregulated innate and adaptive immune responses largely contribute to the SARS-CoV-2 immunopathology (42). On the other hand, SARS-CoV-2 can evade the host immune system and use it to its own advantage. Therefore, the disruption of such immune evasion may play an important role in the development of novel therapeutic approaches to eradicate SARS-CoV-2 infections (46-48).

COVID-19 symptomatology is very heterogeneous and is strictly dependent on the hosts' response: i) Mild, with upper respiratory tract infection and digestive tract impairment; ii) moderate, with lower respiratory tract infection, pneumonia, no obvious hypoxemia with lung lesions; iii) severe, with pneumonia and elevated hypoxemia; and iv) critical, characterized by the appearance of ARDS, septic shock, myocardial and kidney injuries, coagulation dysfunctions (49).

In patients with COVID-19 who have succumbed to the disease, the lung presents diffused bilateral alveolar damage and the formation of a hyaline membrane with the thickening of the alveolar wall (51). Moreover, in a number of cases, a strong accumulation of mononuclear cells and infiltrating macrophages is also present, which occludes the air-exposed surfaces. Following electron microscopy analyses, the SARS-CoV-2 virus has been detected inside bronchial and alveolar type 2 cells. Apart from the lungs, kidney hemorrhage, inflamed liver and neuron degeneration have often been recorded in a number of patients (51).

Additionally, in 70% of deaths, a disseminated intravascular coagulation has also been observed (52). Although vascular endothelial cells express ACE2 receptor, the exact mechanism of such a coagulopathy has not yet been clarified. Moreover, apart from being isolated from the lungs, SARS-CoV-2 viral particles have also been found in urine and stool samples (53). A total of 70% of deaths of patients with COVID-19 were caused by ARDS, whereas the other 30% by complications, including sepsis and multi-organ failure (possibly related to the CS) (54). Sepsis and septic shock have been reported in severe and critical cases (55). In almost 80% of patients with COVID-19 with sepsis, SARS-CoV-2 is the only etiological agent found in both blood and lower respiratory tract specimens, indicating that it is a viral sepsis. Viremia and sepsis are hypothesized to play a pivotal role in the dissemination of SARS-CoV-2 and the subsequent multi-organ damage (56,57).

The immune system of the host plays a fundamental role in the individual outcome of SARS-CoV-2. Based on available data from patients with COVID-19, a recently published medical hypothesis postulated that in mild COVID-19 cases, lung resident macrophages initiated the anti-viral inflammatory response. In turn, macrophages may contain the infection assessed the increased expression of NKG2A and PD-1 inhibitory receptors on T- and NK cell surfaces of patients with COVID-19, suggesting that anticaner immunotherapy could be repurposed as a first line of defense to trigger SARS-CoV-2 clearance (45). In general, SARS-CoV-2 infection may negatively affect the host antiviral immunity at an early stage of the infection process. Importantly, both dysregulated innate and adaptive immune responses largely contribute to the SARS-CoV-2 immunopathology (42). On the other hand, SARS-CoV-2 can evade the host immune system and use it to its own advantage. Therefore, the disruption of such immune evasion may play an important role in the development of novel therapeutic approaches to eradicate SARS-CoV-2 infections (46-48).

COVID-19 symptomatology is very heterogeneous and is strictly dependent on the hosts' response: i) Mild, with upper respiratory tract infection and digestive tract impairment; ii) moderate, with lower respiratory tract infection, pneumonia, no obvious hypoxemia with lung lesions; iii) severe, with pneumonia and elevated hypoxemia; and iv) critical, characterized by the appearance of ARDS, septic shock, myocardial and kidney injuries, coagulation dysfunctions (49).

In patients with COVID-19 who have succumbed to the disease, the lung presents diffused bilateral alveolar damage and the formation of a hyaline membrane with the thickening of the alveolar wall (51). Moreover, in a number of cases, a strong accumulation of mononuclear cells and infiltrating macrophages is also present, which occludes the air-exposed surfaces. Following electron microscopy analyses, the SARS-CoV-2 virus has been detected inside bronchial and alveolar type 2 cells. Apart from the lungs, kidney hemorrhage, inflamed liver and neuron degeneration have often been recorded in a number of patients (51).

Additionally, in 70% of deaths, a disseminated intravascular coagulation has also been observed (52). Although vascular endothelial cells express ACE2 receptor, the exact mechanism of such a coagulopathy has not yet been clarified. Moreover, apart from being isolated from the lungs, SARS-CoV-2 viral particles have also been found in urine and stool samples (53). A total of 70% of deaths of patients with COVID-19 were caused by ARDS, whereas the other 30% by complications, including sepsis and multi-organ failure (possibly related to the CS) (54). Sepsis and septic shock have been reported in severe and critical cases (55). In almost 80% of patients with COVID-19 with sepsis, SARS-CoV-2 is the only etiological agent found in both blood and lower respiratory tract specimens, indicating that it is a viral sepsis. Viremia and sepsis are hypothesized to play a pivotal role in the dissemination of SARS-CoV-2 and the subsequent multi-organ damage (56,57).

The immune system of the host plays a fundamental role in the individual outcome of SARS-CoV-2. Based on available data from patients with COVID-19, a recently published medical hypothesis postulated that in mild COVID-19 cases, lung resident macrophages initiated the anti-viral inflammatory response. In turn, macrophages may contain the infection assessed the increased expression of NKG2A and PD-1 inhibitory receptors on T- and NK cell surfaces of patients with COVID-19, suggesting that anticaner immunotherapy could be repurposed as a first line of defense to trigger SARS-CoV-2 clearance (45). In general, SARS-CoV-2 infection may negatively affect the host antiviral immunity at an early stage of the infection process. Importantly, both dysregulated innate and adaptive immune responses largely contribute to the SARS-CoV-2 immunopathology (42). On the other hand, SARS-CoV-2 can evade the host immune system and use it to its own advantage. Therefore, the disruption of such immune evasion may play an important role in the development of novel therapeutic approaches to eradicate SARS-CoV-2 infections (46-48).
and can trigger the innate and adaptive immune responses that help to clear infection and induce recovery (58).

On the contrary, in severe and/or critical COVID-19 cases, due to the dysregulated immune system, the epithelial-endothelial lung blood barrier is severely damaged, allowing SARS-CoV-2 to attack alveolar and endothelial lung resident cells, thus attracting additional immune cells into the alveoli (59). This accumulation, with a positive feedback loop, exacerbates the local production of cytokines and chemokines, resulting in an uncontrollable pro-inflammatory state (the CS), therefore worsening the lung insult and damage (60). CS during SARS-CoV-2 infection has been ascribed mainly to the rapid viral replication during the first phase of the infection which triggers the pro-inflammatory response of the host (60). Additionally, CoV-derived molecules may induce the accumulation of pro-inflammatory monocytes in the lungs that, as a positive feedback loop, increase the local secretion of cytokines (61). Moreover, lymphocytes attracted to the lungs soon become overactivated and finally exhausted, thereby losing their ability to fight off the infection. Systemically, both the development of a CS and the concurrent lymphopenia, negatively disrupt organ function, resulting in viral sepsis, microcirculation issues and multiorgan dysfunction (62).

An ongoing clinical study, whose preliminary results were published recently by Laing et al., is currently aiming to assess the COVID-19 immune signature, which is a current challenge given the patient heterogeneity (in terms of underlying comorbidities, sex, age, ethnicity etc.). The preliminary findings of the project, termed COVID-IP (COVID-immunophenotyping), revealed distinct features of the immune system in patients with COVID-19, confirming the overproduction of IgG, the presence of a dysregulated cytokine response, disrupted monocyte and dendritic cell phenotype and selective cytopenia in particular T-cell subsets. All these parameters are significantly associated with a worse patient prognosis (63).

Given all these factors, a therapy able to modulate the innate immune response of the host and/or restore a positive and controlled anti-viral adaptive immune reactivity may improve the outcome of patients with COVID-19 (64-66).

3. Management of COVID-19: Prevention, diagnosis and treatment

In order to prevent the spread of COVID-19, the WHO has elaborated standard guidelines, meant to reduce the overall risk of SARS-CoV-2 transmission, which include: i) Hand hygiene; ii) respiratory hygiene/cough etiquette; iii) the use of personal protection equipment based on the risk assessment; and iv) environmental cleaning maintenance rules (67).

Currently, there is no treatment approved by the European Medicines Agency (EMA) or the US Food and Drug Administration (FDA) available for the prevention and cure of COVID-19 (68,69). Since July, 2020, there has been an open debate regarding the approval for the treatment of COVID-19 using a specific inhibitor of viral RNA-dependent RNA polymerase, Remdesivir has exhibited promising preclinical efficacy (70). In spite of this, however, clinical trials have yielded controversial results. The American FDA approved the use of Remdesivir for the treatment of COVID-19, based...
on compelling clinical evidence (i.e., ACTT-1 trial, SIMPLE trials) (71). However, based on the results of the SOLIDARITY WHO-sponsored trial, which did not demonstrate any significant improvement in patients treated with such a molecule, the EMA disposed only a conditional authorization, while the WHO presently discouraged the use of Remdesivir in patients with COVID-19 (72-74).

The management of patients with COVID-19 is mainly based on the provision of supportive care, including oxygen therapy, which represents the main treatment intervention. Although an approved anti-SARS-CoV-2 drug is still lacking, therapy using anti-inflammatories and antivirals is encouraged (75-77). A complete interim guidance produced by the WHO, last updated on May 27, 2020, is currently available, with the main goals of drawing standard procedures to:

i) Attenuate and stop transmission; ii) provide optimized care for all patients; and iii) minimize the impact of the pandemic on the health system and the socio-economical activities (78).

As regards the diagnosis of COVID-19, the WHO document recommends to proceed with the collection of upper respiratory tract specimens (nasopharyngeal and oropharyngeal) for testing by reverse transcription-polymerase chain reaction (RT-PCR). Additionally, where clinical suspicion remains, and tested specimens are negative, the advice is to collect specimens from the lower respiratory tract for further testing. More recently, novel high-sensitive molecular methods based on the usage of the high-sensitive droplet digital PCR have been further proposed for the effective diagnosis of COVID-19 patients with low viral load (79,80). On the contrary, SARS-CoV-2 antibody tests are not recommended by the WHO for the diagnosis of infection with COVID-19. Finally, chest imaging (radiograph, computed tomography scan, ultrasound) may assist in diagnosis and may identify or exclude pulmonary complications (78).

According to a report from the EMA on September 24, 2020, 39 potential COVID-19 vaccines and 163 potential COVID-19 treatments are currently under investigation for their use in human subjects (81). Regarding vaccination, 13 out of 34 candidate vaccines have been so far approved for clinical evaluation, based either on attenuated or inactivated viral particles or on viral-derived nucleic acids or protein subunits (82,83). A summary of the current candidate vaccines under clinical evaluation, adapted from the WHO relative document (updated on June 22, 2020), is reported in Table I (84). Importantly, as of October 11, 2020, preliminary data on two COVID-19 vaccines (one from AstraZeneca and another from BioNTech) are currently under evaluation by the EMA human medicines committee using a rapid rolling review procedure (81).

The heterogeneous development of COVID-19 is strictly dependent on the interaction between SARS-CoV-2 and the individual immune system. SARS-CoV-2 related factors are: The virus genetics, virulence and titer. Individual depending factors are: Genetics (e.g., HLA genes), sex, age, immune system health, as well as the presence of comorbidities (85).

With respect to the ongoing potential treatments under investigation, the currently undergoing clinical trials include:

i) Antiviral drugs; ii) antimalarial drugs; iii) anti-inflammatory molecules; and iv) monoclonal antibodies with activity against components of the immune system. A detailed description of all the available options (out of the scope of the present review)

---

### Table I. Current COVID-19 vaccines under clinical investigation, adapted from a previous study (74).

| Vaccine Strategy                  | Developer                                      | Associated Clinical Trials                  |
|----------------------------------|------------------------------------------------|--------------------------------------------|
| ChAdOx1-S                         | University of Oxford/AstraZeneca               | ISRCTN89951424, 2020-001228-32,            |
| (non-replicating virus)           |                                                | 2020-001072-15                             |
| Adenovirus type 5                 | CanSino Biological/Beijing Institute of Biotechnology | ChiCTR2000031781, ChiCTR2000030906         |
| (non-replicating virus)           |                                                |                                            |
| Nanoparticle-encapsulated viral RNA | Moderna/NIAID                                  | NCT04405076, NCT04283461                  |
| Inactivated virus                 | Wuhan Institute of Biological Products/Sinopharm | ChiCTR2000031809                           |
| Inactivated virus                 | Beijing Institute of Biological Products/Sinopharm | ChiCTR2000032459                           |
| Nanoparticle-encapsulated viral glycoprotein | Sinovac                                      | NCT04383574, NCT04352608                  |
| Nanoparticle-encapsulated viral RNA | BioNTech/Fosun Pharma/Pfizer                   | 2020-001038-36, NCT04368728               |
| Inactivated virus                 | Institute of Medical Biology/Chinese Academy of Medical Sciences | NCT04412538               |
| DNA plasmid vaccine               | Inovio Pharmaceuticals                        | NCT04336410                                |
| Adenovirus (non-replicating virus)| Gamaleya Research Institute                   | NCT04436471, NCT04437875                  |
| Nanoparticle-encapsulated viral RNA | Imperial College London                       | ISRCTN17072692                             |
| Viral RNA                         | Curevac                                       | n.a.                                       |

COVID-19, coronavirus disease 2019; n.a., not available.
is carefully reviewed elsewhere (86-89). A summary of the main drugs currently under clinical investigation, together with their specific features is reported in Table II. A highlight of the leading preventive and therapeutic interventions currently tested with respect to the COVID-19 progression timeline, is reported in Fig. 1.

4. Role of computational biology in the response to COVID-19

The interdisciplinary collaboration from diverse scientific fields is truly relevant in these times. In general, not only is computer science helping to increase the rate of COVID-19 research, it also contributes to the management of severe consequences of the SARS-CoV-2 threat, for healthcare and socio-economical systems, worldwide. A recent review thoroughly described all the modern technologies which are currently helping to tackle the COVID-19 pandemic (90).

Computer science assists by efficiently monitoring and mapping the global spread of the disease, thereby contributing to a more rapid identification of newborn clusters, factors involved in the modulation of the infection rate, as well as to rapidly organize an effective public health response to novel outbreaks (91).

Importantly, bioinformatics represents a fundamental tool for researchers to speed up the process of the identification of drugs and vaccines against COVID-19. A number of web-based platforms have been implemented to promote the public availability of sequences and other complex data, as well as COVID-19-related literature, including the EBI COVID-19 Portal and the NIH SARS-CoV-2 Data Hub (92,93).

In the USA, the White House Office of Science and Technology Policy, the US Department of Energy and IBM founded a public-private partnership, termed the COVID-19 High Performance Computing (HPC) Consortium, aimed at providing researchers globally with massive computing resources, and counting already >100 active projects (94).

With the aid of computational modeling, a number of studies have recently been carried out to predict potential old and novel drug targets, but also candidate vaccines against COVID-19. A Japanese study, recently published in the Journal of Human Genetics - Nature, developed a bioinformatics-based predictive tool for the screening of potential T-cell epitopes for SARS-CoV-2, useful for the better understanding of the immunization dynamic (95). On the same line, a Chinese study developed a virtual screening tool for enzymatic inhibitory molecules, to predict their efficiency to block i) viral cellular entrance, ii) viral replication in the cells, and iii) viral-dependent immune evasion (96). Moreover, another Chinese study developed a drug repurposing platform to assess the efficiency of binding of known protease inhibitors to SARS-CoV-2 enzyme, in order to identify potential effective molecules (97). Another multicenter study set up a computational method to

| Drug                      | Primary pathology                  | Mechanism of action                                | Target                        |
|---------------------------|-----------------------------------|----------------------------------------------------|-------------------------------|
| Hydroxychloroquine        | Malaria                           | Cellular endocytosis inhibitor                      | SARS-CoV-2                    |
| Chloroquine               | Malaria                           | Cellular endocytosis inhibitor                      | SARS-CoV-2                    |
| Remdesivir                | Ebola virus                       | Viral RNA-dependent RNA polymerase inhibitor        | SARS-CoV-2                    |
| Favipiravir               | Huma influenza virus; Ebola virus | Viral RNA-dependent RNA polymerase inhibitor        | SARS-CoV-2                    |
| Lopinavir/Ritonavir       | Human immunodeficiency virus      | Viral protease inhibitor                            | SARS-CoV-2                    |
| Ribavirin                 | Hepatitis C virus                 | Viral RNA-dependent RNA polymerase inhibitor        | SARS-CoV-2                    |
| Thalidomide               | Cancer                            | Immunomodulatory                                    | Host immune system            |
| Human immunoglobulin      | Primary immunodeficiency          | Anti-inflammatory                                   | Host immune system            |
| Heparin                   | Coagulopathies                    | Anticoagulant, anti-inflammatory                    | Host immune system            |
| Corticosteroids           | Inflammatory diseases             | Anti-inflammatory                                   | Host immune system            |
| Tocilizumab               | Rheumatoid arthritis              | Monoclonal antibody against IL-6 receptor           | Host immune system            |
| Sarilumab                 | Rheumatoid arthritis              | Monoclonal antibody against IL-6 receptor           | Host immune system            |
| Canakinumab               | Rheumatoid arthritis              | Monoclonal antibody against IL-1β                    | Host immune system            |
| Anakinra                  | Rheumatoid arthritis              | Human IL-1 receptor antagonist protein              | Host immune system            |
| Gimsilumab                | Inflammatory diseases; cancer     | Monoclonal antibody against GM-CSF                  | Host immune system            |
| Baricitinib               | Rheumatoid arthritis              | Janus kinase inhibitor; anti-inflammatory           | Host immune system            |
| Ruxolitinib               | Myelofibrosis                     | Janus kinase inhibitor; anti-inflammatory           | Host immune system            |
| Nivolumab                 | Cancer                            | Monoclonal antibody against PD-1                    | Host immune system            |

COVID-19, coronavirus disease 2019; SARS-CoV-2, severe acute respiratory syndrome associated coronavirus-2; IL, interleukin; GM-CSF, granulocyte-macrophage colony-stimulating factor; PD-1, programmed death-1.
track and map single cell RNA-sequencing. The application to COVID-19 patient specimens proved that this tool may be applied for the identification of the molecular signatures involved in pathogenesis of SARS-CoV-2, thereby assisting in the identification of novel druggable targets (98). For example, using network proximity analyses of drug targets and CoV-host interactions, Zhou et al identified potential repurposable drugs against COVID-19 (99).

Predictive algorithms are also under rapid development, with the goal of identifying an effective SARS-CoV-2 vaccine. For example, an American study performed a bioinformatics analysis to screen potential S protein features which may be highly immunogenic (100). Computer simulation may also accelerate the search for an effective vaccine. Importantly, a study carried out at the University of Catania, in Italy, led to the development of a useful platform to predict in silico, the efficiency of selected anti-SARS-CoV-2 monoclonal antibodies in generating an adequate host immune response (101). The Universal Immune System Simulator (UISS) is able to simulate the dynamics of single entities of the immune system, following a stimulus or a therapeutic intervention, by using an agent-based methodology. This methodology already provided useful prediction for the development of SARS-CoV-2 vaccines. This platform may be applied in the future for the effective screening of novel and existing candidate vaccines against SARS-CoV-2 (101). On the same line, Kar et al from Bangalore University (India) used a computational approach to design a suitable candidate multi-epitope vaccine against SARS-CoV-2 (102). In conclusion, computational approaches and prediction platforms may be applied for the effective screening of potential vaccination and therapeutic strategies against SARS-CoV-2, with the aim of remodulating the impaired immune system to in SARS-CoV-2 infected individuals.

5. Immune-checkpoint inhibitors against COVID-19: A lesson learnt from cancer

The outcome of COVID-19 has been reported to be more severe in patients with co-existing pathologies, which are associated with an impaired immune system (6). For example, elderly subjects or individuals with comorbidities, such as diabetes, obesity, hypertension or cancer, possess an immune system that cannot efficiently contain and combat SARS-CoV-2 infection. In these cases, COVID-19, may rapidly degenerate towards a severe or critical status (6,103,104).

Of note, cancer is a multifactorial disease often associated with viral or bacterial infections. In particular, several studies have demonstrated a direct involvement of certain viruses (HBV, HCV, HPV, etc.) in the pathogenesis of tumors (105,106). On the other hand, cancer patients are highly vulnerable to infections, including SARS-CoV-2. They represent fragile subjects, as the cancer itself may be associated with an extensive immunosuppressive state (107) or as their immunosuppression may be exacerbated by myelosuppressive therapies, such as chemotherapy or radiotherapy (108).

Given their immune-compromised status, cancer patients infected by SARS-CoV-2 may be at a higher risk of developing ARDS, septic shock and acute myocardial infarction (109-111). An early nationwide study conducted in China demonstrated that cancer patients have a significantly higher risk of developing COVID-19 and of suffering severe complications (112). A larger and more recent clinical study performed on 928 cancer patients affected by COVID-19, confirmed that an increased 30-day mortality was associated with age, male sex, smoking and an active cancer status (113). Importantly, that clinical study, confirmed by several others, found that while the presence of comorbidities aggravated the mortality rate associated with COVID-19, the provision of chemotherapy, targeted therapy, or immunotherapy was not associated with an increased mortality in cancer patients (114-118). Possibly, the effects of a more advanced malignant disease may explain the overall severity of infection, as well as the COVID-19-associated death toll (119).

The question remains of how to take care of cancer patients to protect them from SARS-CoV-2. Recent recommendations, based on observations made on lung cancer patients, suggest to weigh the impact of interrupting any programmed cancer treatment, using a case-by-case approach, as there is no universal solution to oncological care during this pandemic. To note a warning from the authors was: ‘primum nil nocere’ (first do no harm) (120,121).

ICIs, including anti-PD-1, anti-PD ligand-1 (PD-L1) and anti-CTLA-4 antibodies, represent an innovative therapy for the treatment of numerous solid tumors, as well as some hematological malignancies (ie., certain lymphomas) (122) as they restore cellular-mediated immunocompetence (123-126).

As said, chemotherapies and radiotherapies may induce myelosuppression; therefore they lower the overall humoral, as well as the cellular mediated immune response (127). On the contrary, cancer patients treated with ICIs have been demonstrated to be able to restore their immunocompetence during HIV, hepatitis B, or hepatitis C viral infection, suggesting that these individuals may be highly immunocompetent compared to the other cancer patients undergoing chemotherapy or radiotherapy (128).

In rare cases, cancer patients who have undergone ICI therapy, may develop lung immune-related adverse events (irAEs), including pneumonia. This should be taken into consideration as a risk factor in cancer patients affected by COVID-19 and under ICI therapeutic regimens (129). In spite of this, a recent analysis of a cohort of patients affected by lung cancer (TERA VOLT), suggested that ICI-based therapy did not increase the overall mortality risk in cancer patients affected by COVID-19. Coherently, Gonzalez-Cao et al observed, through a retrospective analysis, of 50 cancer patients included in the Spanish registry, that anticancer immunotherapy did not significantly increase the risk of mortality by COVID-19 in melanoma patients (130). However, while the therapy itself may not affect the infection risk, the fragility of cancer patients represents an issue that needs to be assessed with a greater attention being paid in terms of protective care for these exposed individuals (110).

ICIs may restore individual cellular-mediated immunocompetence and this lesson from cancer may be transferred to non-cancer COVID-19 patients. ICIs have been already used beyond cancer for the treatment of, for example, sepsis-induced immunosuppression (131,132). Moreover, ICIs were safely administered to cancer patients vaccinated for influenza virus (133,134). Overall, ICIs are a promising tool to be studied against infective diseases, including SARS-CoV-2 (135,136).
The cytokine release syndrome, determining the CS, is an important complication in patients with severe SARS-CoV-2 infection, as it may lead to ARDS (27). As widely described in the section above, following a first hyper-inflammatory phase triggered by the CS, SARS-CoV-2 prolonged infection may induce T-cell hyperactivation and finally exhaustion, associated with concurrent lymphopenia in patient (137). High pro-inflammatory IL-6 levels, together with an elevated exhaustion and reduced functional diversity of T-cells in peripheral blood, may predict poorer outcomes of patients with COVID-19 (138). Although both CD4+ and CD8+ T-cells in patients with COVID-19 are produced, particularly against the SARS-CoV-2 S antigen, such cells are reduced in abundance and are less activated in the case of severe SARS-CoV-2 infection. Therefore, the viral clearance may be delayed. Additionally, the excessive exhaustion of CD8+ T-cells in patients with severe COVID-19 may reduce their cellular-mediated immune response to the virus (138,139). In detail, peripheral T-cells are impaired and express high levels of both the immunosuppressive markers, mucin-3 and PD-1, which deeply impairs their effector functionality (137). In association with this T-cell disruption, patients with severe and critical COVID-19 may develop viral sepsis (57). The identification of a therapy to restore the T-cell functionality in patients with COVID-19 may be used to prevent viral sepsis and therefore, the development of ARDS.

In a previous study, PD-1/PD-L1 blocking antibodies administered to mice chronically infected with lymphocytic choriomeningitis virus, enhanced the viral control and virus-specific CD8+ T-cell responses, demonstrating that the PD-1 inhibitory pathway is of particular importance in exhausted T-cell formation. Following the PD-1/PD-L1 blockage, T-cells CD8+ restarted to proliferate in lymphoid and non-lymphoid tissues. Importantly, the effect seemed to be specific for PD-1/PD-L1, as anti-CTLA-4 blocking antibody administration had no effect on either T-cell function or viral control (140). In line with these results, PD-1 inhibition was also found relevant in human viral disease. In fact, HIV-infected patients were shown to exhibit T-cell exhaustion with a high PD-1 expression. In such subjects, PD1-blocking antibodies restored both CD4+ and CD8+ T-cell abundance and functionality (141).

Based on results obtained with other models of viral infections, in both mice and humans, the use of ICIs (and in particular anti-PD-1 antibody) has been suggested by several authors for the treatment of SARS-CoV-2-infected subjects, alone or in combination with the concurrent blockage of the pro-inflammatory IL-6 pathway (142-145). The rationale behind this co-administration is to contemporarily block both the detrimental humoral CS with anti-IL-6 pathway-targeting antibodies, in association with restoring T-cell cellular-mediated immunity, by using the anti-PD-1 antibodies (146). These two treatments, if used in synergy, may re-educate the defeated host immune system to finally wipe off the SARS-CoV-2 infection. Importantly, it has also been suggested that an earlier anti-PD-1 intervention in patients with COVID-19 may block the
development of ARDS, and thus minimize the need for further ICU support (143). Alternatively, anti-PD-1 administration may be associated with other modulators of the innate immunity, such as Toll-like receptor (TLR) agonists/antagonists, as recently suggested (64).

Based on the reported observations, it seems reasonable to suggest that ICIs may be used in both cancer and non-cancer patients affected by COVID-19 (147). Indeed, 5 clinical studies are currently registered at clinicaltrials.gov with the common goal of studying the potentialities of administering anti-PD-1 antibody to cure COVID-19.

The first one is being conducted on metastatic and advanced cancer patients, affected by COVID-19 and which are not eligible for a transfer to an ICU. It is a French, phase II, prospective, controlled, randomized study, which has already enrolled 384 patients since its opening. The study will assess the difference in the efficacy to eradicate SARS-CoV-2 infection between COVID-19 patients treated with anti-PD-1 antibody nivolumab in association with standard care protocol, versus standard care protocol offered alone (NCT04339914).

Notably, the other 4 registered studies will be enrolling and testing the safety and the efficacy of anti-PD-1 administration on non-cancer COVID-19-infected patients. The first one is a Chinese, phase II, interventional randomized study, aimed at recruiting a total of 120 COVID-19-infected patients. Given that PD-1 is a key mediator of T-cell depletion and viral sepsis in patients with COVID-19, the investigators would like to assess the clinical efficacy of PD-1 blockade (administering a PD-1 blocking antibody), in association with standard of care treatments, in COVID-19-infected patients with pneumonia and lymphocytopenia (NCT04268537).

A second, Hong Kong, phase II, interventional, open-label, controlled pilot study on 15 adult patients with COVID-19 has been set up to evaluate: i) The efficacy of anti-PDL1 antibody (nivolumab) in clearing the SARS-CoV-2 infection; and ii) the safety of the anti-PD1 treatment in COVID-19-infected patients. In that study, nivolumab will be administered in association with the optimal standard supportive care for COVID-19 (NCT04356508).

A third French, phase II, interventional randomized study will recruit about 100 COVID-19-infected patients which will be treated with standard of care with or without nivolumab administration. As in previous studies, the primary goal is to assess the time required for clinical improvement and the overall efficacy of administering anti-PD-1 antibody to patients with COVID-19 (NCT04343414).

A fourth, French, phase II, randomized study, is enrolling 120 obese COVID-19-infected patients, to evaluate the efficacy of anti-PD-1 nivolumab in treating severe forms of COVID-19 in such high-risk class of infected subjects. Obesity markedly increases the risk of developing a severe, or even critical, form of COVID-19 (103). Obese individuals develop a chronic meta-inflammatory status associated with a dysregulated immune system. This obesity-related status is called inflammaging (148). That study will be divided into 2 arms. All participants will receive routine standard of care for COVID-19, while one arm will receive anti-PD-1 nivolumab in combination (NCT04413838).

These clinical studies hold immense potential in that they may soon uncover the hidden capability of ICIs, that have revolutionized the field of oncology over the past 10 years, and may thus identify a cure for severe cases of COVID-19. A summary of the expected effects of anti-PD-1 administration is presented in Fig. 2.

6. Conclusions and future perspectives

Over the past 10 months, the threat of COVID-19 has led to a marked increase in both research and medical efforts internationally, with the collective aim of identifying a successful cure with which to eradicate SARS-CoV-2. Although standard care protocols and guidelines have been elaborated in order to ameliorate the outcomes of patients with COVID-19 and to contain the global spread of the disease, a cure has not yet been identified. Research has moved forward at a rapid pace and, regarding the vaccine, as of December 2, 2020 the UK gave emergency authorization to the Pfizer and BioNTech’s vaccine. As of December 8, 2020, the UK began the vaccination campaign, which will be soon followed by Canada and other nations.

A number of drugs have been adapted from other pathologies to either block viral entry and intracellular replication or to redirect the impaired immune system of compromised severe and critical COVID-19-infected patients.

As regards the host immune system remodulation, two clinical approaches are currently tested in patients. On the one hand, tests are ongoing to identify molecules able to block the exacerbated CS that is responsible for extensive multi-organ damage and ultimately death. This category of molecules includes monoclonal antibodies and small molecules targeting both the IL-6 and IL-1 pro-inflammatory pathways, which may reduce unrestrained cytokine production. On the other hand, novel trials are exploring specific ICIs able to re-activate the exhausted T-cell immune response, and thus prevent important COVID-19-related complications, including viral septicemia. For example, it is hoped that in COVID-19-infected patients, anti-PD-1 monoclonal antibodies, which are already being used in cancer patients to re-activate the immune system against cancer cells may restore the cytotoxic activity of T-cells, particularly CD8+ cytotoxicity against the SARS-CoV-2 pathogen. It may be possible in the future to extend the study of ICIs by also blocking PD-L1 expressed by infected cells; however, additional translational studies will be required.

The vast number of clinical trials on COVID-19-infected patients that have begun at the onset of 2020 will undoubtedly uncover a huge quantity of novel results, hopefully leading to the identification of valid therapies and vaccines that may help humanity to overcome this testing and troublesome time in history.

Acknowledgements

The authors would like to acknowledge the Italian League Against Cancer (LILT) for its support. The authors would like to specially thank Dr Golnar Kolahgar, University of Cambridge, for her support with the English language revision and editing of this manuscript.

Funding

No funding was received.
Availabilty of data and materials

The original contributions presented in the study are publicly available. These data can be found at: www.pubmed.com; www.clinicaltrials.gov.

Authors' contributions

ML conceptualized and supervised the drafting of the manuscript and provided critical revisions. SV assisted in the conceptualization of the manuscript and wrote the first draft of the manuscript, including the drawing of the 2 figures and the preparation of the both tables. LF, FT, GS, RB, DAS and GRu contributed to the writing of the contents presented in Chapters 1, 2 and 5 and both tables of the manuscript, GRu contributed to the writing of the contents presented in Chapters 3 and 4 of the manuscript. All authors contributed to manuscript revision, and read, and approved the final manuscript.

Ethics approval and consent to participate

Not applicable.

Patient consent for publication

Not applicable.

Competing interests

DAS is the Editor-in-Chief for the journal, but had no personal involvement in the reviewing process, or any influence in terms of adjudicating on the final decision, for this article. The other authors declare that the review was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

References

1. Chan JW, Yuan S, Kok KH, To KK, Chu H, Yang J, Xing F, Liu J, Yip CC, Poon RW, et al: A familial cluster of pneumonia associated with the 2019 novel coronavirus indicating person-to-person transmission: A study of a family cluster. Lancet 395: 514-523, 2020.
2. Lu R, Zhao X, Li J, Niu P, Yang B, Wu H, Wang W, Song H, Huang B, Zhu N, et al: Genomic characterisation and epidemiology of 2019 novel coronavirus: Implications for virus origins and receptor binding. Lancet 395: 565-574, 2020.
3. World Health Organization (WHO): Coronavirus disease (COVID-19): Situation reports. https://www.who.int/emergencies/diseases/novel-coronavirus-2019/situation-reports.
4. Gu W, Liu Y, Su Q, Han Y, Chen Y, Li X, Chen X, et al: Structural view of SARS-CoV-2 RNA replication machinery: Implications for understanding the pathophysiology of severe and critical conditions of COVID-19: Demon or Angel? Viruses 12: 491, 2020.
5. Romano M, Ruggiero A, Squeglia F, Maga G and Berisio R: A structural view of SARS-CoV-2 RNA replication machinery: RNA synthesis, proofreading and final capping. Cells 9: 1267, 2020.
6. Kaye M, Duche J, Tran T, Kostecich R, Chibo D, Morris J, Catton M and Birch C: SARS-associated coronavirus replication in cell lines. Emerg Infect Dis 12: 128-133, 2006.
7. Yap JKY, Moriyama Y and Iwasaki A: Immune responses and antibody responses as therapeutic targets for COVID-19. J Immunol 205: 507-312, 2020.
8. Li S, Jiang L, Li X, Lin F, Wang Y, Li B, Jiang T, An W, Liu S, Liu H, et al: Clinical and pathological investigation of patients with severe COVID-19. JCI Insight 5: e138070, 2020.
9. Di Giacomo S, Tang Y, Romano M, Lussini A, Mancini D, Mattioli B, et al: The key molecule for understanding the pathophysiology of severe and critical conditions of COVID-19: Demon or Angel? Viruses 12: 491, 2020.
10. Hoffmann M, Klein-weber H and Pühlmann S: A multibasic cleavage site in the spike protein of SARS-CoV-2 is essential for infection of human lung cells. Mol Cell 78: 779-784.e5, 2020.
11. Devaux CA, Rolain J-M and Raoult D: ACE2 receptor polymorphism: susceptibility to SARS-CoV-2, hypertension, multi-organ failure, and COVID-19 disease outcome. J Microbiol Immunol Infect 53: 425-435, 2020.
12. Zou X, Chen K, Zou J, Han P, Hao J and Han Z: Single-cell RNA-seq data analysis on the receptor ACE2 expression reveals the potential risk of different human organs vulnerable to 2019-nCoV infection. Front Med 14: 185-192, 2020.
13. Xiao L, Sakagami H and Miwa N: ACE2: The key molecule for understanding the pathophysiology of severe and critical conditions of COVID-19: Demon or Angel? Viruses 12: 491, 2020.
14. Romano M, Ruggiero A, Squeglia F, Maga G and Berisio R: A Structural view of SARS-CoV-2 RNA replication machinery: RNA synthesis, proofreading and final capping. Cells 9: 1267, 2020.
15. Kaye M, Duche J, Tran T, Kostecich R, Chibo D, Morris J, Catton M and Birch C: SARS-associated coronavirus replication in cell lines. Emerg Infect Dis 12: 128-133, 2006.
16. Yap JKY, Moriyama Y and Iwasaki A: Immune responses and antibody responses as therapeutic targets for COVID-19. J Immunol 205: 507-312, 2020.
17. Li S, Jiang L, Li X, Lin F, Wang Y, Li B, Jiang T, An W, Liu S, Liu H, et al: Clinical and pathological investigation of patients with severe COVID-19. JCI Insight 5: e138070, 2020.
18. Shah A: Novel coronavirus-induced NLRP3 Inflammasome activation: a potential drug target in the treatment of COVID-19. Front Immunol 11: 1021, 2020.
19. Coperchini F, Chiovato L, Croce L, Magri F and Rotondi M: The cytokine storm in COVID-19: An overview of the involvement of the chemokine/chemokine receptor system. Cytokine Growth Factor Rev 35: 23-32, 2020.
20. Ye Q, Wang B and Mao J: The pathogenesis and treatment of the ‘Cytokine Storm’ in COVID-19. J Infect 80: 607-613, 2020.
21. Liu F, Li L, Xu M, Wu J, Luo D, Zhu Y, Li B, Song X and Zhou X: Prognostic value of interleukin-6, C-reactive protein, and procalcitonin in patients with COVID-19. J Clin Virol 127: 104370, 2020.
22. Ong EZ, Chan YFZ, Leong WY, Lee NMY, Kalimuddin S, HajaMohideen SM, Chan KS, Tan AT, Bertolletti A, Ooi EE, et al: A dynamic immune response shapes COVID-19 progression. Cell 181: 1016-1035.e19, 2020.
23. Fan EJ, Liu L, Wang Z, Liu P, Li Y, Xu W, Wei L, Liu S, et al: Clinical and pathological investigation of patients with severe COVID-19. JCI Insight 5: e138070, 2020.
24. Bakri H, Mokhtar F, Albayati A, Zayed A, El Ali F, Ebel T, et al: Clinical and pathological investigation of patients with severe COVID-19. JCI Insight 5: e138070, 2020.
25. Bakri H, Mokhtar F, Albayati A, Zayed A, El Ali F, Ebel T, et al: Clinical and pathological investigation of patients with severe COVID-19. JCI Insight 5: e138070, 2020.
26. Bai Y, Yao L, Wei Y, Wei X, Duan R, Li X, Sun Z, et al: Sensitivity analysis of the case-fatality rate of COVID-19 in China: A meta-analysis. Med Sci Monit 26: e925738, 2020.
et al: The Third International Consensus

et al: A dynamic COVID-19 immune

et al: Zinc and respiratory tract infections: Perspectives

et al: The presence of SARS-CoV-2 RNA in the feces of COVID-19 patients. J Med Virol 92: 833-840, 2020.

et al: Pulmonary non-postmortem findings in a series of COVID-19 cases from northern Italy: A two-centre descriptive study. Lancet Infect Dis 20: 1135-1140, 2020.

et al: Pulmonary non-postmortem findings in a series of COVID-19 cases from northern Italy: A two-centre descriptive study. Lancet Infect Dis 20: 1135-1140, 2020.

et al: Innate immunity in COVID-19 and multiorgan response. Curr Protoc Cardiol 45: 100618, 2020.

et al: The Third International Consensus Definitions for Sepsis and Septic Shock (Sepsis-3). JAMA 315: 801-810, 2016.

et al: What has been learned and to be learned about the novel coronavirus disease. Int J Biol Sci 16: 1753-1766, 2020.

et al: Hypothesis for potential pathogenesis of SARS-CoV-2 infection—a review of immune changes in patients with viral pneumonia. Emerg Microbes Infect 9: 727-732, 2020.

et al: Marked T cell activation, senescence, exhaustion and skewing in patients with coronavirus disease 2019 (COVID-19). Future Sci OA 6: FS6005, 2020.

et al: Zinc and respiratory tract infections: Perspectives

et al: A dynamic COVID-19 immune

et al: Zinc and respiratory tract infections: Perspectives

et al: The Third International Consensus

et al: Zinc and respiratory tract infections: Perspectives

et al: The Third International Consensus

et al: Zinc and respiratory tract infections: Perspectives
116. Dai M, Liu D, Liu M, Zhou F, Li G, Chen Z, Zhang Z, You H, Wu M, Zheng Q, et al: Patients with cancer appear more vulnerable to SARS-COV-2: A multi-center study during the COVID-19 outbreak. Cancer Discov 10: 783-791, 2020.

117. Robiotti EV, Babady NE, Mead PA, Rolling T, Perez-Johnston R, Bernardes M, Bogler Y, Caldararo M, Figueroa CJ, Glickman MS, et al: Determinants of COVID-19 disease severity in patients with cancer. Nat Med 26: 1218-1223, 2020.

118. Horn L, Whisnant JG, Torri V, Huang L-C, Trama A, Paz-Ares LG, Felip E, Panchal V, De Tomà A, Tiseo M, et al: Thoracic Cancers International COVID-19 Collaboration (TERAVOLT): Impact of type of cancer therapy and COVID therapy on survival. J Clin Oncol 38 (Suppl 18): LBA111, 2020.

119. Russell B, Moss C, Papa S, Irshad S, Ross P, Spencer J, Kordasti S, Crawley D, Wylie H, Cahill F, et al: Factors affecting COVID-19 outcomes in cancer patients: a first report from guy's cancer center in London. Front Oncol 10: 1279, 2020.

120. Banna G, Curioni-Foncatedro A, Friedlaender A and Addeo A: How we treat patients with lung cancer during the SARS-CoV-2 pandemic: Primum non nocere. ESMO Open 5 (Suppl 2): e000765, 2020.

121. Derosa L, Melenotte C, Griscelli F, Gachot B, Marabelle A, Kroemer G and Zitvogel L: The immuno-oncological challenge of COVID-19. Nat Cancer 1: 946-964, 2020.

122. Darvin P, Toor SM, Sassadhan Nair V and Elkord E: Immune checkpoint inhibitors: Recent progress and potential biomarkers. Exp Mol Med 50: 1-11, 2018.

123. La-Beck NM, Nguyen DT, Le AD, Alzghari SK and Trinh ST: Optimizing Patient Outcomes with PD-1/PD-L1 Immune Checkpoint Inhibitors for the First-Line Treatment of Advanced Non-Small Cell Lung Cancer. Pharmacotherapy 40: 239-255, 2020.

124. Leonardi GC, Candido S, Falzone L, Spandidos DA and Libra M: Cutaneous melanoma and the immunotherapy revolution (Review). Int J Oncol 57: 609-618, 2020.

125. Falzone L, Salomone S and Libra M: Evolution of cancer pharmacological treatments at the turn of the third millennium. Front Pharmacol 9: 1300, 2018.

126. Christofi T, Baritaki S, Falzone L, Libra M and Zaravinos A: Current perspectives in cancer immunotherapy. Cancers (Basel) 11: 1472, 2019.

127. May JE, Donaldson C, Gyna L and Morse HR: Chemotherapy-induced genotoxic damage to bone marrow cells: Long-term implications. Mutagenesis 33: 241-251, 2018.

128. Shah NJ, Al-Shboul G, Blackburn M, Cook M, Belouali A, Liu SV, Madhavan S, He AR, Atkins MB, Gibney GT, Liu XQ and Zheng YT: Elevated exhaustion levels and reduced functional diversity of T cells in peripheral blood may predict severe progression in COVID-19 patients. Cell Mol Immunol 17: 533-535, 2020.

129. Bruno G, Nasiolli V, Tagliafico E, Trenti T and Luppi M: COVID-19: Room for treating T cell exhaustion? Crit Care 24: 229, 2020.

130. Buonaguro FM, Puzanov I and Ascieto PA: Anti-IL6R role in treatment of COVID-19-related ARDS. J Transl Med 18: 165, 2020.

131. Arnaudiez FI, O'Day SJ, Drake CG, Fox BA, Fu B, Urba WJ, Montesarchio V, Weber JS, Wei H, Wigginton JM, et al: The Society for Immunotherapy of Cancer perspective on regulation of interleukin-6 signaling in COVID-19-related systemic inflammatory response. J Immunother Cancer 8: e000930, 2020.

132. Maio M, Hamid O, Larkin J, Covre A, Altomonte M, Calabrò L, Vardhana SA, Robert C, Ibrahim R, Anichini A, et al: Immune checkpoint inhibitors for cancer therapy in the COVID-19 era. Clin Cancer Res 26: 4201-4205, 2020.

133. Chong CR, Park VJ, Cohen B, Postow MA, Wolchok JD and Kamboj M: Safety of inactivated influenza vaccine in cancer patients receiving immune checkpoint inhibitors. Clin Infect Dis 70: 193-199, 2020.

134. Bayle A, Khettab M, Lucibello F, Chamsheddie AN, Goldschmidt V, Perret A, Ropert S, Scotté F, Loulergue PJ and Mir O: Immunogenicity and safety of influenza vaccination in cancer patients receiving checkpoint inhibitors targeting PD-1 or PD-L1. Ann Oncol 31: 959-961, 2020.